Dan Lewis is a Project Farma life sciences manufacturing leader who works with pharma, biotech, and advanced-therapy organizations on technical operations and manufacturing.
Dan Lewis is useful for practical analysis of biopharma manufacturing, capacity, supply chains, and technical operations.
Best for
Biopharma manufacturing consultancies and campaigns on radiopharmaceutical supply chains and technical operations.
Not for
Consumer health sponsored placements or campaigns expecting direct product purchases.
Key takeaways
Manufacturing problems are solved across disciplines, not inside one.
Big facility investments are about supply-chain control, not just capacity.
Radiopharmaceuticals are the next oncology platform, and isotope supply is the strategic bottleneck.
Check first: Confirm figures, sources, commercial formats, audience data and Project Farma relationship before contact.
Main ideas
Manufacturing problems are solved across disciplines, not inside one of them · Big facility investments are about supply-chain control, not just capacity · Radiopharmaceuticals are the next oncology platform, and isotope supply is the strategic bottleneck
Dan Lewis is a life sciences manufacturing leader at Project Farma, with a stated focus on client solutions across pharma, biotech and advanced therapies.
Their LinkedIn posts cover manufacturing investments, industry news and operational challenges.
They are worth following for a practical lens on how manufacturing capacity, supply chains and coordinated technical work affect the delivery of therapies.
Lewis connects industry developments to their operational implications.
A post about radiopharmaceutical investment, for example, frames isotope supply and manufacturing infrastructure as strategic constraints in oncology, though it does not name the deals behind its aggregate investment figure.
Posts about Novartis and AstraZeneca connect facility investments to capacity, supply-chain resilience and patient access.
In a different register, they draw on Project Farma’s SimoTech acquisition to argue that engineering, quality, automation, digital systems and operations need to work together across a facility’s lifecycle.
That mix—trend interpretation alongside a stated operating philosophy—is more distinctive than the broad news roundup, which summarizes many stories with less individual analysis.
The posts provide useful starting points for readers interested in biopharma manufacturing; verify reported figures and claims against original sources before reusing them.
Dan Lewis argues from the operating side of life sciences manufacturing, rather than from markets or science.
Read more
Three arguments recur: complex manufacturing problems are solved by aligning disciplines rather than optimising one; large facility investments are about supply-chain control and patient access, not just capacity; and new platforms such as radiopharmaceuticals and AI should be judged by what they change in operations, supply and governance. They also prioritise breadth, tracking deals, regulation, workforce and policy across the industry in a mix of broad roundups and occasional thesis posts.
Manufacturing problems are solved across disciplines, not inside one of them
Dan Lewis argues that digital manufacturing and automation now run through the entire facility lifecycle — design, project execution, CQV, start-up, operational readiness and ongoing operations.
Read more
Optimising engineering, quality, automation or operations separately misses the real constraint; aligning those functions on shared objectives reduces handoffs and speeds delivery to patients.
Writing about the completed acquisition of SimoTech by Project Farma and PerkinElmer, Dan Lewis says the most complex manufacturing challenges are rarely solved by optimising one discipline in isolation. They highlight fewer handoffs, stronger execution and faster delivery of therapies as client benefits, and welcome incoming colleague Pat Desmond by name.
Big facility investments are about supply-chain control, not just capacity
Dan Lewis reads a company's disclosed capital commitment as a decision about where complex therapies are made and how safely they reach patients.
Read more
Localising production shortens the supply chain and reduces delivery risk; the size of a commitment signals how seriously the company treats that control. They place individual announcements within a wider pattern of onshoring.
On AstraZeneca's move of its rare disease portfolio to the United States, Dan Lewis explains the plans for two Maryland sites: Frederick will expand to nearly double commercial biologics capacity, while Gaithersburg will add a drug substance facility.
The initiative will create 300 new jobs, and Dan concludes that it is about enhancing control as much as increasing capacity.
They name Novartis and Moderna as examples of complex manufacturing consolidating in the United States.
A separate post on Novartis's $771 million North Carolina investment makes the same point, looking beyond 700,000 square feet to the speed and scale of delivering advanced therapies, then asking readers what they think about the Research Triangle's biotech ecosystem.
Radiopharmaceuticals are the next oncology platform, and isotope supply is the strategic bottleneck
Dan Lewis argues that while attention went to AI, GLP-1 obesity medicines and antibody-drug conjugates, radiopharmaceuticals have been building quietly into what could become oncology's next major treatment platform.
Read more
The case rests on four claims: these treatments are transforming precision oncology; AI should improve patient selection and personalised dosimetry; theranostics is changing drug-development economics; and isotope supply may become one of the industry's most valuable strategic assets.
The post says that over two years Novartis, Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical leaders committed more than $10 billion to radiopharmaceutical acquisitions, manufacturing infrastructure and isotope supply. The figure is Dan Lewis's aggregate framing, not a list of named deals, suppliers or studies.
Judge AI adoption by operations and governance, not by the model
Dan Lewis covers AI in pharma through its effects on discovery, manufacturing, supply chain, distribution and workforce capability, as well as the guardrails around it.
Read more
They relay the view that AI augments scientists rather than replacing them, and treat data governance and human oversight as part of the story, not an afterthought.
Summarising Novo Nordisk's partnership with OpenAI, Dan Lewis lists AI deployment across drug discovery, manufacturing, supply chains and commercial operations.
They note the aim to accelerate R&D and surface new drug candidates through large-scale data analysis, and repeat the company's line that AI will "supercharge" scientists.
Dan also highlights workforce AI literacy and strict data governance with human oversight, framing the deal as a bid for speed in competitive obesity and metabolic disease research.
Keep a wide watch on the whole industry, not just manufacturing
Dan Lewis prioritises breadth of intake.
Read more
They use a digest format to track deals, regulatory turnover, job cuts, top-selling drugs, counterfeit-medicine enforcement, EU supply policy and early-stage funding in one post, pairing each item with a short implication instead of building a single argument. This sits alongside deeper thesis posts: the account moves between broad aggregation and occasional analysis.
One roundup covers twelve stories, including Bristol Myers Squibb's $15.2 billion licensing deal with Jiangsu Hengrui, the departure of FDA Commissioner Marty Makary, Takeda's plan to cut 4,500 jobs, Eli Lilly's Mounjaro becoming the world's top-selling drug in Q1 2026, INTERPOL's seizure of six million illicit medicines, and Isomorphic Labs' $2.1 billion Series B.
Each is presented as the creator's summary.
Ask for the sources behind the items.
Dan Lewis's posts vary in format: the radiopharmaceutical post advances a thesis with supporting claims, while the roundup aggregates headlines. The choice appears to depend on whether they have an argument to make about a development, not on the subject area.
Talent and client-side execution are part of the manufacturing problem
Dan Lewis treats hiring and relationship-building as strategic, not administrative.
Read more
In recruiting senior operations leaders, they call for deep industry expertise paired with innovative thinking, and seek people who shape manufacturing rather than simply consult. In their own role, Dan describes deepening partnerships across pharma, biotech and advanced therapy sectors and helping organisations improve speed, predictability and execution across technical operations and manufacturing.
A Project Farma hiring post seeks a Vice President of Manufacturing and Technical Operations and a Vice President of Reliability and Asset Management, citing bio/pharma manufacturing, technical operations, engineering, reliability, maintenance and asset management leadership as relevant backgrounds. Dan Lewis's promotion announcement to Vice President of Client Solutions describes years of relationship building and operational leadership, and names the partnership and execution goals of the new role.
This answers the question 'what does Dan Lewis think is coming next in oncology manufacturing?' Start here: it is the closest thing in the posts to an argument rather than a summary of the day's headlines, and it directly addresses radiopharmaceutical supply chains.
Read more
Dan Lewis argues that while attention went to AI, GLP-1 obesity drugs and antibody-drug conjugates, a quieter shift has been happening in radiopharmaceuticals.
The post states that over two years Novartis, Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical leaders committed more than $10 billion to radiopharmaceutical acquisitions, manufacturing infrastructure and isotope supply.
Four short claims follow: radiopharmaceuticals are transforming precision oncology, AI is expected to improve patient selection and dosimetry, theranostics is changing drug-development economics, and isotope supply may become one of the industry's most valuable strategic assets.
It is a thesis post rather than a news report.
Ask for named deals, suppliers and studies, and sources for the aggregate figure.
For brands planning a campaign
A strong anchor for a co-authored piece on radiopharmaceutical supply-chain trends.
The post asserts the $10 billion figure and isotope-supply claim without naming deals or suppliers.
Ask for named transactions, isotope-sourcing constraints, manufacturing-capacity details and sources for the figures.
It answers 'how does Dan Lewis read a single company investment as an industry trend?' Start here to see the interpretive move they make repeatedly: take one disclosed capital figure and connect it to supply-chain resilience and patient access.
Read more
Dan Lewis explains AstraZeneca's decision to relocate its entire rare disease portfolio to the United States as part of a $3.5 billion commitment, which they place inside a larger $50 billion U.S. commitment.
Two sites are named: Frederick, Maryland, expanding to nearly double commercial biologics capacity, and Gaithersburg, Maryland, adding a new drug substance facility.
The post reports 300 new jobs and frames the move as strengthening the BioHealth Capital Region.
The argument is that the investment is about control as much as capacity: localising complex therapies shortens the supply chain and reduces delivery risk.
It closes by listing AstraZeneca alongside Novartis and Moderna as evidence that complex manufacturing is consolidating in the United States.
For brands planning a campaign
Useful support for a supply-chain resilience angle and for anyone weighing onshoring as a theme.
The named site-level detail (two Maryland sites, capacity and job numbers) gives a co-authored piece concrete hooks.
Ask for the sources for those figures before publication.
It answers 'what does Dan Lewis consider the significant part of a manufacturing expansion?' Start here to see the breakdown-and-question format that runs through their facility posts: headline numbers, a short list of specifics, a claim about what it means for patients, then an open question to the audience.
Read more
Dan Lewis breaks down a $771 million Novartis investment in new biologics, small molecule and fill/finish manufacturing, expected to create up to 700 jobs.
The structured breakdown lists two new facilities in Durham plus one in Morrisville, roughly 700,000 square feet, 700 Novartis roles and about 3,000 indirect jobs by 2030, nearly doubling the company's operational footprint in North Carolina.
The post moves beyond square footage to the speed and scale of delivering advanced therapies, then asks readers what they think about the rapid expansion of the Research Triangle's biotech ecosystem.
Four topic hashtags close it out.
For brands planning a campaign
A ready-made format for a sponsored discussion or comment-driving post about site selection and manufacturing capacity.
The closing audience question gives a brand something to build around.
Ask for sources for the investment figures before using them in a co-authored follow-up.
It answers 'how does Dan Lewis cover AI in pharma manufacturing?' Start here because the post is typical of their AI coverage: adoption framed through operations and governance rather than model technology, with attention to what it changes for the workforce.
Read more
Dan Lewis summarises Novo Nordisk's partnership with OpenAI in three bullet points: AI deployed across drug discovery, manufacturing, supply chains and commercial operations; aims to accelerate R&D, improve efficiency and surface new drug candidates through large-scale data analysis; and the company's position that AI will 'supercharge' scientists rather than replace them.
A closing block adds workforce AI literacy, efficiency gains across manufacturing, supply chain and distribution, and strict data governance with human oversight.
The framing is competitive: speed of drug development in obesity and metabolic disease is presented as the advantage being bought.
For brands planning a campaign
A clean entry point if the campaign angle touches AI adoption in manufacturing or supply chain. The post stresses human oversight and ethical use, giving a co-authored piece a basis for practical oversight questions rather than a repeat of the announcement.
It answers 'what does Dan Lewis actually believe about how manufacturing projects should be run?' Start here for the clearest statement of their operating philosophy, and one of the few posts written from direct experience rather than reporting someone else's announcement.
Read more
This post marks the completed acquisition of SimoTech by Project Farma and PerkinElmer and uses it to make an operating argument.
Dan Lewis says digital manufacturing and automation now touch every stage of the facility lifecycle, from design and project execution through CQV, start-up, operational readiness and ongoing operations.
The central claim is that the hardest manufacturing problems are rarely solved by optimising one discipline in isolation, and that engineering, quality, automation, digital systems and operations aligned on the same objectives produce the best outcomes.
Client benefits are listed as fewer handoffs, stronger execution and faster delivery of therapies.
A named colleague, Pat Desmond, is welcomed at the end.
For brands planning a campaign
The strongest evidence that Dan Lewis can speak from practice about CQV, operational readiness and digital manufacturing, not just comment on headlines. The post is closely tied to their employer's commercial interest, so treat sponsored use as vendor-adjacent and disclose that relationship.
It answers 'what does Dan Lewis pay attention to across the whole industry?' Start here to see the breadth of their news intake and judge whether the account is a specialist commentary source or a high-volume aggregator.
Read more
An emoji-led digest of twelve stories: Bristol Myers Squibb's $15.2B licensing deal with Jiangsu Hengrui across 13 early-stage oncology, haematology and immunology programmes; the departure of FDA Commissioner Marty Makary and the firing of acting drug centre head Tracy Beth Hoeg; Takeda's plan to cut 4,500 jobs by March 2027; Eli Lilly's Mounjaro becoming the world's top-selling drug in Q1 2026 at $8.7B, overtaking Merck's Keytruda; Daiichi Sankyo's aim to quadruple oncology revenue by 2030; INTERPOL's Operation Pangea XVIII seizing six million illicit medicines across 90 countries and shutting 6,000 fraudulent websites; the EU's provisional Critical Medicines Act deal covering about 270 essential drugs; Moderna's early mRNA hantavirus research; Isomorphic Labs' $2.1B Series B; Boehringer Ingelheim's licensing of a preclinical Immunitas antibody worth up to €407.5M; REGENXBIO's Duchenne gene therapy hitting its pivotal trial goal with two serious side effects complicating investor reaction; metabolic fatty liver disease affecting 1.3 billion people and possibly 1.8 billion by 2050; and CREATE Medicines' $122M Series B.
For brands planning a campaign
This post shows Dan Lewis is willing to publish a broad recurring digest format, which is sponsorable, but also where their own judgement is thinnest.
For a thought-leadership brief, use it as evidence of reach and consistency, not as a model for co-authored analysis.
It answers “who is Dan Lewis at work, and what are they responsible for?”
Read more
Start here for a brief overview of their role and remit before reading how they apply it to industry news.
Dan Lewis announces a promotion to Vice President of Client Solutions at Project Farma, crediting years of relationship building, operational leadership and collaboration across life sciences.
In the new role, they will deepen partnerships across pharma, biotech and advanced therapy sectors and help organisations improve speed, predictability and execution across technical operations and manufacturing.
They thank mentors, teammates, clients and partners and look ahead to the work ahead.
For brands planning a campaign
Context rather than a work sample: it establishes the commercial remit (client solutions, partnerships, technical operations) that shapes which topics they post about. Useful for judging whether a co-authored article would fit their role; read it alongside the SimoTech post to assess the vendor-relationship disclosure question.
It answers “how does Dan Lewis use their channel beyond commentary?”
Read more
Start here to see how they describe the skills the manufacturing sector needs and ask their audience to act.
A recruitment post announcing two senior openings at Project Farma: Vice President of Manufacturing and Technical Operations, and Vice President of Reliability and Asset Management.
Writing in the company’s voice, Lewis says the best teams combine deep industry expertise with innovative thinking and seeks leaders who want to shape life sciences manufacturing rather than simply consult.
Relevant backgrounds include bio/pharma manufacturing, technical operations, engineering, reliability, maintenance or asset management leadership.
The post invites readers to share it or tag a strong fit.
For brands planning a campaign
The weakest sample for a thought-leadership brief and a poor co-authoring model, but useful for understanding the account’s audience: senior manufacturing and technical operations professionals. Lewis also makes direct asks of them.
Dan Lewis publishes curated digests covering deals, regulatory shifts, workforce cuts, top-selling drugs, supply-security policy, and early-stage biotech funding.
Read more
Each roundup groups several developments with brief implications rather than building one deep argument.
For brands planning a campaign
A manufacturing consultancy could adapt this format as a co-branded quarterly industry scan, but the roundup is broad, not manufacturing-specific. It works best for top-of-funnel awareness rather than as a technical thought-leadership anchor.
Posts analyze Novartis's $771M North Carolina manufacturing investment and AstraZeneca's $2B rare disease manufacturing relocation tied to a $3.5B U.S. commitment.
Read more
Dan Lewis treats each as more than square footage, focusing on supply-chain resilience, patient access, local control, and job creation. In the AstraZeneca post, they note that the Maryland expansion will add 300 high-tech jobs and conclude that complex manufacturing is being established in the United States.
Breaks down scope, impact, and legacy, then closes with a question for readers.
For brands planning a campaign
This is the closest fit to a biopharma manufacturing consultancy's thought-leadership brief. A co-authored piece could pair Dan Lewis's capacity-investment framing with the consultancy's technical operations expertise in site selection, CQV, and operational readiness.
Integrated manufacturing lifecycle and digital manufacturing
In the Project Farma and PerkinElmer SimoTech acquisition post, Dan Lewis argues that digital manufacturing and automation now touch every stage, from design and project execution through CQV, start-up, operational readiness, and ongoing operations.
Read more
They say complex manufacturing challenges are rarely solved by optimizing one discipline in isolation; the best outcomes align engineering, quality, automation, digital systems, and operations around shared objectives.
For brands planning a campaign
Supports a co-authored article on integrated project delivery, reducing handoffs, and aligning automation with CQV. For a consultancy, this topic shows a specific operating philosophy, not just general news awareness.
Dan Lewis argues that radiopharmaceuticals are an underappreciated oncology shift, noting more than $10B committed by Novartis, Bristol Myers Squibb, AstraZeneca, Eli Lilly, and others to acquisitions, manufacturing infrastructure, and isotope supply.
Read more
They highlight how theranostics are changing drug-development economics and isotope supply is becoming a strategic asset, with AI expected to improve patient selection and personalized dosimetry.
Source the $10B figure independently; Dan Lewis's post does not name a specific source.
For brands planning a campaign
Directly relevant to the proposed co-authored article on radiopharmaceutical supply-chain trends. Dan Lewis can provide platform-level framing on why RLT matters and where manufacturing and isotope supply become strategic.
Dan Lewis covered Novo Nordisk's partnership with OpenAI to deploy AI across drug discovery, manufacturing, supply chains, and commercial operations.
Read more
They relay Novo Nordisk's view that AI will supercharge scientists rather than replace them, and flag data governance and human oversight.
For brands planning a campaign
A consultancy could develop an angle on AI in technical operations, but this post is partnership news rather than manufacturing-specific analysis. Pairing it with CQV or digital-manufacturing evidence would make the topic actionable.
Manufacturing talent and technical operations leadership
A Project Farma hiring post calls for leaders in manufacturing and technical operations, as well as reliability and asset management.
Read more
Dan Lewis frames the need as combining deep industry expertise with innovative thinking to help shape the future of life sciences manufacturing.
For brands planning a campaign
Supports content on workforce planning, technical operations leadership, and asset management, making it useful for a consultancy's employer-brand or talent-adjacent campaigns. It is less differentiated than the capacity and radiopharmaceutical topics.
Dan Lewis announced a promotion to Vice President of Client Solutions at Project Farma, describing work to deepen partnerships across pharma, biotech, and advanced therapy sectors and help organizations accelerate speed, predictability, and execution across technical operations and manufacturing.
Read more
For brands planning a campaign
Establishes the commercial context for a consultancy collaboration: Dan Lewis is positioned to speak about client solutions, partnership building, and execution across technical operations. It provides context rather than a standalone topic pillar.
Dan Lewis’s clearest documented business relationship is employment at Project Farma, where they said they were promoted to Vice President of Client Solutions.
Read more
A post about the completed SimoTech acquisition also mentions PerkinElmer and SimoTech. Ask Dan to clarify any ownership or commercial relationships with those companies, or any sponsorship, affiliate, investment, or partnership arrangements.
Project Farma
Employment
Dan Lewis said they were promoted to Vice President of Client Solutions at Project Farma and described working across pharma, biotech, and advanced therapy sectors on technical operations and manufacturing.
Dan Lewis covers life sciences manufacturing: where complex therapies are made, how supply chains are controlled, and what new platforms like radiopharmaceuticals and AI change in operations.
Read more
Start with the analyses of AstraZeneca's rare disease onshoring and Novartis's North Carolina investment, then read the radiopharmaceuticals post for a platform-level view.
The industry roundups offer a broad scan of deals, regulation, and workforce shifts.
For adjacent perspectives, Bilal Bham covers commercial and market-access strategy for radiopharma and psychedelics, Hussain Mooraj covers cell and gene therapy access and manufacturing economics, and Armin Metzger covers biosimilar manufacturing and supply operations.
Bilal Bham also analyses biopharma developments—such as radiopharmaceuticals and psychedelic medicine—and draws out commercial, regulatory, and market-access implications.
Read more
Like Dan Lewis, they focus on what changes in the business rather than just reporting the science.
Bilal Bham's lens is commercial strategy, market access, and regulatory narratives, often tied to a newsletter and articles. Dan Lewis focuses on manufacturing operations, facility investments, and technical execution across engineering, quality, and supply chain.
Hussain Mooraj writes about advanced therapies, manufacturing economics, and patient access.
Read more
They highlight operational details—like a COGS under $8,000 for a cell therapy—and connect them to commercial and access challenges, overlapping with Dan Lewis's focus on manufacturing as a strategic issue.
Hussain Mooraj centers on cell and gene therapy access, reimbursement, and cross-industry collaboration through working groups. Dan Lewis focuses on biopharma manufacturing capacity, onshoring, and technical operations execution.
Armin Metzger posts about manufacturing and supply operations, biosimilar production at scale, and patient access.
Read more
Like Dan Lewis, they treat manufacturing capacity and supply chain as central to delivering therapies, and reflect on building end-to-end accountability in technical operations.
Armin Metzger writes from an executive leadership position, sharing company announcements and personal career reflections from Ferring and Sandoz. Dan Lewis offers industry analysis and commentary across many companies, with a broader external view.
Dan Lewis’s posts cover facility investment, supply chains, technical operations, automation, and emerging treatment platforms relevant to pharma, biotech, and life-sciences manufacturing professionals.
Read more
For a radiopharmaceutical supply-chain campaign, ask for documented data on followers’ demographics, job roles, and seniority, as well as post reach and recent performance for comparable oncology and manufacturing posts.
Dan Lewis posts on LinkedIn as a Project Farma leader about life sciences manufacturing, covering company deals, plant investments, hiring, and industry news.
Read more
None of the eight posts is sponsored, discloses a paid partnership, or states a sponsorship offer, media kit, rate card, or partnership inquiry route.
Novartis, AstraZeneca, Novo Nordisk, Bristol Myers Squibb, Takeda, Eli Lilly, and other brands appear in industry news items, not as commercial partners; a company hashtag does not indicate payment.
These posts do not document a partnership product available to book.
Before planning a sponsored placement, ask whether a sponsorship or collaboration format exists and request its terms.
Dan Lewis offers close commentary on manufacturing and supply-chain moves—the post on radiopharmaceutical investment across Novartis, Bristol Myers Squibb, AstraZeneca, and Eli Lilly is the clearest example—making the subject-matter overlap for a potential collaboration visible, even though the commercial terms are not.
Strong subject fit for a co-authored article. Independently check the article’s evidence and confirm collaboration terms.
Read more
Brief
A biopharma manufacturing consultancy wants a thought-leadership article on radiopharmaceutical supply chains.
Campaign angle
What will it take to scale radiopharmaceuticals? Examine isotope sourcing, manufacturing capacity and the operational links needed to deliver these therapies reliably. Dan Lewis can frame the industry shift, while the consultancy contributes technical analysis and documented examples. Dan Lewis’s posts do not name sources for the claim of more than $10 billion in commitments. Verify that figure and add specific transactions and supply details before publication. Since Dan Lewis writes about Project Farma, disclose any relevant employer relationship.
Why
Dan Lewis’s post on radiopharmaceuticals connects oncology’s emerging treatment platform with manufacturing infrastructure and isotope supply, giving the article a relevant starting thesis. Other posts interpret industry developments through capacity, supply-chain resilience and patient access. A post about integrating automation, quality, engineering and operations offers useful manufacturing context, though it concerns a separate Project Farma acquisition.
When to choose a specialist
Poor fit. Don’t book on the assumption that Dan Lewis offers sponsored placements or can deliver consumer reach.
Read more
Brief
A consumer health brand wants a paid LinkedIn placement to drive immediate purchases of an over-the-counter product.
Why
The posts focus on biopharma, manufacturing and industry developments, not consumer health recommendations or product sales. No sponsorship format, rate card or inquiry route is published. Before reconsidering, request confirmation of available commercial formats and documented audience and performance data relevant to the campaign’s target audience.
A worked campaign example
Campaign angle
From isotope bottleneck to reliable supply: the manufacturing questions behind radiopharmaceutical growth.
Evidence and checks
Use the radiopharmaceutical post as a starting point, not as substantiation for the investment total. Independently source the cited commitments, identify the relevant isotopes and supply constraints, and have technical claims reviewed by qualified experts. Confirm co-authoring terms and any necessary disclosures before commissioning. Next, hold a short scoping call with a proposed outline and a list of evidence the consultancy can supply.
Execution
Co-author a practical article that starts with Dan Lewis’s observation that isotope supply may become a strategic asset, then tests that thesis against named evidence. Organize it around three questions: where isotope availability constrains supply, what manufacturing capacity and logistics are required, and how companies can plan for dependable delivery. Use the consultancy’s documented technical expertise for the operational analysis; ask Dan Lewis to develop the industry framing. Include a short checklist for readers assessing a proposed facility or supply-chain investment.
Better when the article needs a market-maturity and access-strategy lens on radiopharmaceuticals.
Read more
Their posts track the first US radioligand therapy approved through an abbreviated generic pathway, the proposed Telix–ITM combination as isotope production moves into corporate strategy, and the argument that differentiation may come from route, formulation, and personalised delivery rather than a new ligand. That is closer to the supply-chain and competitive dynamics a consultancy could build a co-authored piece around.
You trade Dan Lewis's broad industry-roundup framing for a narrower market-access and narrative-integrity argument.
The posts point to a longer article but do not contain it, so the consultancy would need to retrieve and verify the original analysis.
Their posts do not demonstrate the facility lifecycle, CQV, or operational-readiness detail shown in their Project Farma posts, so pair Bham with a technical co-author if the campaign requires manufacturing execution depth.
Better when the consultancy wants to widen the campaign from radiopharmaceuticals to advanced therapies access and delivery.
Read more
Their posts describe the NextGen Therapy EMEA working group and Deloitte's advanced therapies summit, including a sub-$8,000 COGS example, Europe's commercialisation gap, outcomes-based pricing, clinical-to-commercial planning, treatment-site readiness, AI use, and supply-chain enablement. For a thought-leadership article about how manufacturing economics and health-system readiness determine patient access, that is a stronger base than radiopharma-specific trend framing.
The posts do not address isotope sourcing or radiopharmaceutical manufacturing, so using Mooraj changes the campaign decision rather than answering it.
They are event-based and reference a LinkedIn community hub.
Ask for source data to support the COGS or policy claims.
You would need separate technical input for a radiopharma supply-chain article or re-scope the campaign toward cell and gene therapy access.
Better when the article needs a senior manufacturing and supply-chain operator's view on scaling biologic production and reliable supply.
Read more
Metzger's posts describe ten years at Ferring, work on manufacturing and supply operations, two FDA approvals, and the opening of Sandoz's high-volume biosimilar manufacturing centre in Lendava, Slovenia, tied to a Bio100 ambition of more than 100 biosimilars by 2040. That gives the consultancy a named facility, a supply-network story, and a quality-and-access frame it can examine.
The posts are about biosimilars, not radiopharmaceuticals, and do not discuss isotope sourcing or radioligand therapy.
The Sandoz post is an opening announcement rather than a technical analysis, so specific capacity, cost, or logistics claims would need verification.
The consultancy would also need to disclose the Sandoz relationship if Metzger contributes.
Choose Metzger for a companion or adjacent manufacturing-scale piece; keep Dan Lewis for the radiopharma thesis.
This profile draws on eight LinkedIn posts Dan Lewis published publicly.
The posts cover industry news roundups, facility investments, AI adoption, manufacturing services and recruiting, and radiopharmaceutical investment analysis.
Post-level publication dates are not included in the posts here, so no date range is claimed; they are a recent slice rather than a full-lifetime body of work.
Reported figures and company plans are presented as Dan Lewis reported them and would need independent sourcing before reuse.
Dan Lewis's posts do not establish whether they have a signature book, show, or earlier body of work; targeted identity research is needed to address that gap.
